Potential Possibilities of HPV DNA Detection in Liquid Biopsy for Diagnosis of Patients with Head and Neck Cancer

1 Peck K., Sher Y.P., Shih J.Y., Roffler S.R., Wu C.W., Yang P.C.: Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res. 58, 2761–2765 (1998) PeckK. SherY.P. ShihJ.Y. RofflerS.R. WuC.W. YangP.C. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients Cancer Res. 58 2761 2765 1998 Search in Google Scholar

2 Schwarzenbach H., Alix-Panabières C., Müller I., Letang N., Vendrell J.P., Rebillard X., Pantel K.: Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res. 15, 1032–1038 (2009) SchwarzenbachH. Alix-PanabièresC. MüllerI. LetangN. VendrellJ.P. RebillardX. PantelK. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer Clin. Cancer Res. 15 1032 1038 2009 10.1158/1078-0432.CCR-08-191019188176 Search in Google Scholar

3 Punnoose E.A., Lackner M.R. i wsp.: Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18, 2391–2401 (2012) PunnooseE.A. LacknerM.R. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib Clin. Cancer Res. 18 2391 2401 2012 10.1158/1535-7163.TARG-11-PR-3 Search in Google Scholar

4 Kidess-Sigal E, Jeffrey S.S i wsp.: Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget, 7, 85349–85364 (2016) Kidess-SigalE JeffreyS.S Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer Oncotarget 7 85349 85364 2016 10.18632/oncotarget.13350535674127863403 Search in Google Scholar

5 Higgins M.J., Park B.H i wsp.: Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 18, 3462–3469 (2012) HigginsM.J. ParkB.H Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood Clin. Cancer Res. 18 3462 3469 2012 10.1158/1078-0432.CCR-11-2696353337022421194 Search in Google Scholar

6 Zhu G., Ye X., Dong Z., Lu Y. C., Sun Y., Liu Y., McCormack R., Gu Y., Liu X.: Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. J. Mol. Diagn. 17, 265–272 (2015) ZhuG. YeX. DongZ. LuY. C. SunY. LiuY. McCormackR. GuY. LiuX. Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer J. Mol. Diagn. 17 265 272 2015 10.1016/j.jmoldx.2015.01.00425769900 Search in Google Scholar

7 Thierry A.R., Ychou M. i wsp.: Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 20, 430–435 (2014) ThierryA.R. YchouM. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Nat. Med. 20 430 435 2014 10.1038/nm.351124658074 Search in Google Scholar

8 Yang Y., Shen X., Li R., Shen J., Zhang H., Yu L., Liu B., Wang L.: The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC. Oncotarget, 8, 49773–49782 (2017) YangY. ShenX. LiR. ShenJ. ZhangH. YuL. LiuB. WangL. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC Oncotarget 8 49773 49782 2017 10.18632/oncotarget.17937556480628572536 Search in Google Scholar

9 Mazurek A.M., Rutkowski T., Fiszer-Kierzkowska A., Małusecka E., Składowski K.: Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral Oncol. 54, 36–41 (2016) MazurekA.M. RutkowskiT. Fiszer-KierzkowskaA. MałuseckaE. SkładowskiK. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients Oral Oncol. 54 36 41 2016 10.1016/j.oraloncology.2015.12.00226786940 Search in Google Scholar

10 D’Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., Westra W.H., Gillison M.L.: Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356, 1944–1956 (2007) D’SouzaG. KreimerA.R. ViscidiR. PawlitaM. FakhryC. KochW.M. WestraW.H. GillisonM.L. Case-control study of human papillomavirus and oropharyngeal cancer N. Engl. J. Med. 356 1944 1956 2007 10.1056/NEJMoa06549717494927 Search in Google Scholar

11 Lohavanichbutr P., Chen C. i wsp.: Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch. Otolaryngol. Head Neck Surg. 135, 180–188 (2009) LohavanichbutrP. ChenC. Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices Arch. Otolaryngol. Head Neck Surg. 135 180 188 2009 10.1001/archoto.2008.540276182919221247 Search in Google Scholar

12 Mehanna H., Beech T., Nicholson T., El-Hariry I., McConkey C., Paleri V., Roberts S.: Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head & Neck, 35, 747–755 (2013) MehannaH. BeechT. NicholsonT. El-HariryI. McConkeyC. PaleriV. RobertsS. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region Head & Neck 35 747 755 2013 10.1002/hed.22015 Search in Google Scholar

13 Ganguly N., Parihar S.P.: Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J. Biosci. 34, 113–123 (2009) GangulyN. PariharS.P. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis J. Biosci. 34 113 123 2009 10.1007/s12038-009-0013-7 Search in Google Scholar

14 Faridi R., Zahra A., Khan K., Idrees M.: Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol. J. 8, 1–8 (2011) FaridiR. ZahraA. KhanK. IdreesM. Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer Virol. J. 8 1 8 2011 10.1186/1743-422X-8-269 Search in Google Scholar

15 Mack D.H., Laimins L.A.: A keratinocyte-specific transcription factor, KRF-1, interacts with AP-1 to activate expression of human papillomavirus type 18 in squamous epithelial cells. Proc. Natl. Aca.d Sci. USA, 88, 9102–9106 (1991) MackD.H. LaiminsL.A. A keratinocyte-specific transcription factor, KRF-1, interacts with AP-1 to activate expression of human papillomavirus type 18 in squamous epithelial cells Proc. Natl. Aca.d Sci. USA 88 9102 9106 1991 10.1073/pnas.88.20.9102 Search in Google Scholar

16 Yoon C.S., Kim K.D., Park S.N., Cheong S.W.: alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP. Biochem. Biophys. Res. Commun. 283, 668–673 (2001) YoonC.S. KimK.D. ParkS.N. CheongS.W. alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP Biochem. Biophys. Res. Commun. 283 668 673 2001 10.1006/bbrc.2001.4838 Search in Google Scholar

17 Walline H.M., Carey T.E. i wsp.: High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA Otolaryngol. Head Neck Surg. 139, 1320–1327 (2013) WallineH.M. CareyT.E. High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods JAMA Otolaryngol. Head Neck Surg. 139 1320 1327 2013 10.1001/jamaoto.2013.5460 Search in Google Scholar

18 Lont A.P., Kroon B.K., Horenblas S., Gallee M.P., Berkhof J., Meijer C.J., Snijders P.J.: Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int. J. Cancer, 119, 1078–1081 (2006) LontA.P. KroonB.K. HorenblasS. GalleeM.P. BerkhofJ. MeijerC.J. SnijdersP.J. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival Int. J. Cancer 119 1078 1081 2006 10.1002/ijc.21961 Search in Google Scholar

19 Kulasingam S.L., Hughes J.P., Kiviat N.B., Mao C., Weiss N.S., Kuypers J.M., Koutsky L.A.: Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA, 288, 1749–1757 (2002) KulasingamS.L. HughesJ.P. KiviatN.B. MaoC. WeissN.S. KuypersJ.M. KoutskyL.A. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral JAMA 288 1749 1757 2002 10.1001/jama.288.14.1749 Search in Google Scholar

20 Lee S.A., Song Y.S. i wsp.: Multiple HPV infection in cervical cancer screened by HPVDNA Chip. Cancer Lett. 198, 187–192 (2003) LeeS.A. SongY.S. Multiple HPV infection in cervical cancer screened by HPVDNA Chip Cancer Lett. 198 187 192 2003 10.1016/S0304-3835(03)00312-4 Search in Google Scholar

21 Münger K., Yee C.L., Phelps W.C., Pietenpol J.A., Moses H.L., Howley P.M.: Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65, 3943–3948 (1991) MüngerK. YeeC.L. PhelpsW.C. PietenpolJ.A. MosesH.L. HowleyP.M. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences J. Virol. 65 3943 3948 1991 10.1128/jvi.65.7.3943-3948.1991 Search in Google Scholar

22 Havre P.A., Yuan J., Hedrick L., Cho K.R., Glazer P.M.: p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 55, 4420–4424 (1995) HavreP.A. YuanJ. HedrickL. ChoK.R. GlazerP.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells Cancer Res. 55 4420 4424 1995 Search in Google Scholar

23 Hiller T., Poppelreuther S., Stubenrauch F., Iftner T.: Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol. Biomarkers Prev. 15, 1262–1267 (2006) HillerT. PoppelreutherS. StubenrauchF. IftnerT. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification Cancer Epidemiol. Biomarkers Prev. 15 1262 1267 2006 10.1158/1055-9965.EPI-05-0778 Search in Google Scholar

24 Wallin K.L., Wiklund F., Angström T., Bergman F., Stendahl U., Wadell G., Hallmans G., Dillner J.: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Eng.l J. Med. 341, 1633–1638 (1999) WallinK.L. WiklundF. AngströmT. BergmanF. StendahlU. WadellG. HallmansG. DillnerJ. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer N. Eng.l J. Med. 341 1633 1638 1999 10.1056/NEJM199911253412201 Search in Google Scholar

25 de Visser K.E., Korets L.V., Coussens L.M.: De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell, 7, 411–423 (2005) de VisserK.E. KoretsL.V. CoussensL.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent Cancer Cell 7 411 423 2005 10.1016/j.ccr.2005.04.014 Search in Google Scholar

26 Ylitalo N., Adami H.O. i wsp.: A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res. 60, 6027–6032 (2000) YlitaloN. AdamiH.O. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ Cancer Res. 60 6027 6032 2000 Search in Google Scholar

27 Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., Zur Hausen H.: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature, 314, 111–114 (1985) SchwarzE. FreeseU.K. GissmannL. MayerW. RoggenbuckB. StremlauA. Zur HausenH. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells Nature 314 111 114 1985 10.1038/314111a0 Search in Google Scholar

28 Scheffner M., Werness B.A., Huibregtse J.M., Mayer W., Roggenbuck B., Stremlau A., Zur Hausen H.: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63, 1129–1136 (1990) ScheffnerM. WernessB.A. HuibregtseJ.M. MayerW. RoggenbuckB. StremlauA. Zur HausenH. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 Cell 63 1129 1136 1990 10.1016/0092-8674(90)90409-8 Search in Google Scholar

29 Dong W., Tommasino M. i wsp.: Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J. Virol. 79, 14899–14908 (2005) DongW. TommasinoM. Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38 J. Virol. 79 14899 14908 2005 10.1128/JVI.79.23.14899-14908.2005128756616282489 Search in Google Scholar

30 Hagensee M.E., Yaegashi N., Galloway D.A.: Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67, 315–322 (1993) HagenseeM.E. YaegashiN. GallowayD.A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins J. Virol. 67 315 322 1993 10.1128/jvi.67.1.315-322.19932373658380079 Search in Google Scholar

31 Liu X., Clements A., Zhao K., Marmorstein R.: Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 281, 578–586 (2006) LiuX. ClementsA. ZhaoK. MarmorsteinR. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor J. Biol. Chem. 281 578 586 2006 10.1074/jbc.M50845520016249186 Search in Google Scholar

32 Santer F.R., Moser B., Spoden G.A., Jansen-Dürr P., Zwerschke W.: Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation. Carcinogenesis, 28, 2511–2520 (2007) SanterF.R. MoserB. SpodenG.A. Jansen-DürrP. ZwerschkeW. Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation Carcinogenesis 28 2511 2520 2007 10.1093/carcin/bgm19917827406 Search in Google Scholar

33 Vogt M., Butz K., Dymalla S., Semzow J., Hoppe-Seyler F.: Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene, 25, 4009–4015 (2006) VogtM. ButzK. DymallaS. SemzowJ. Hoppe-SeylerF. Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein Oncogene 25 4009 4015 2006 10.1038/sj.onc.120942916462759 Search in Google Scholar

34 Iovino F, Lentini L, Amato A, Di Leonardo A.: RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol. Cancer, 5, 1–11 (2006) IovinoF LentiniL AmatoA Di LeonardoA. RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts Mol. Cancer 5 1 11 2006 10.1186/1476-4598-5-38161325416987420 Search in Google Scholar

35 Dalal S., Gao Q., Androphy E.J., Band V.: Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol. 70, 683–688 (1996) DalalS. GaoQ. AndrophyE.J. BandV. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells J. Virol. 70 683 688 1996 10.1128/jvi.70.2.683-688.19961898678551603 Search in Google Scholar

36 Camus S., Menéndez S., Cheok C.F., Stevenson L.F., Lain S., Lane D.P.: Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene, 26, 4059–4070 (2007) CamusS. MenéndezS. CheokC.F. StevensonL.F. LainS. LaneD.P. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6 Oncogene 26 4059 4070 2007 10.1038/sj.onc.1210188274271317224909 Search in Google Scholar

37 Jabbar S., Strati K., Shin M.K., Pitot H.C., Lambert P.F.: Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology, 407, 60–67 (2010) JabbarS. StratiK. ShinM.K. PitotH.C. LambertP.F. Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice Virology 407 60 67 2010 10.1016/j.virol.2010.08.003294645920797753 Search in Google Scholar

38 Rutkowski T., Składowski K.: Impact of human papillomavirus (HPV) on pathogenesis, treatment and prognosis of head and neck cancer. Współczesna Onkol. 13, 233–240 (2009) RutkowskiT. SkładowskiK. Impact of human papillomavirus (HPV) on pathogenesis, treatment and prognosis of head and neck cancer Współczesna Onkol. 13 233 240 2009 Search in Google Scholar

39 Koopman L.A., Szuhai K., van Eendenburg J.D., Bezrookove V., Kenter G.G., Schuuring E., Tanke H., Fleuren G.J.: Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res. 59, 5615–5624 (1999) KoopmanL.A. SzuhaiK. van EendenburgJ.D. BezrookoveV. KenterG.G. SchuuringE. TankeH. FleurenG.J. Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines Cancer Res. 59 5615 5624 1999 Search in Google Scholar

40 Ziegert C., Wentzensen N., Vinokurova S., Kisseljov F., Einenkel J., Hoeckel M., von Knebel Doeberitz M.: A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene, 22, 3977–3984 (2003) ZiegertC. WentzensenN. VinokurovaS. KisseljovF. EinenkelJ. HoeckelM. von Knebel DoeberitzM. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques Oncogene 22 3977 3984 2003 10.1038/sj.onc.120662912813471 Search in Google Scholar

41 Peitsaro P., Johansson B., Syrjänen S.: Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J. Clin. Microbiol. 40, 886–891 (2002). PeitsaroP. JohanssonB. SyrjänenS. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique J. Clin. Microbiol. 40 886 891 2002 10.1128/JCM.40.3.886-891.200212027511880410 Search in Google Scholar

42 Wagatsuma M., Hashimoto K., Matsukura T.: Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flanking sequences. J. Virol. 64, 813–821 (1990) WagatsumaM. HashimotoK. MatsukuraT. Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flanking sequences J. Virol. 64 813 821 1990 10.1128/jvi.64.2.813-821.1990 Search in Google Scholar

43 Lace M.J., Anson J.R., Klussmann J.P., Wang D.H., Smith E.M., Haugen T.H., Turek L.P.: Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers. J. Virol. 85, 1645–1654 (2011) LaceM.J. AnsonJ.R. KlussmannJ.P. WangD.H. SmithE.M. HaugenT.H. TurekL.P. Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers J. Virol. 85 1645 1654 2011 10.1128/JVI.02093-10302887521123375 Search in Google Scholar

44 Matovina M., Sabol I., Grubisić G., Gašperov N.M., Grce M.: Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. Gynecol. Oncol. 113, 120–127 (2009) MatovinaM. SabolI. GrubisićG. GašperovN.M. GrceM. Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions Gynecol. Oncol. 113 120 127 2009 10.1016/j.ygyno.2008.12.00419157528 Search in Google Scholar

45 Olthof N.C., Huebbers C.U. i wsp.: Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLoS One, 9, e88718 (2014) OlthofN.C. HuebbersC.U. Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression PLoS One 9 e88718 2014 10.1371/journal.pone.0088718393333124586376 Search in Google Scholar

46 Walline H.M., Carey T.E. i wsp.: Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck, 39, 840–852 (2017) WallineH.M. CareyT.E. Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines Head Neck 39 840 852 2017 10.1002/hed.24729539218428236344 Search in Google Scholar

47 Olthof N.C., Speel E.J.M. i wsp.: Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. Int. J. Cancer, 136, E207–218 (2015) OlthofN.C. SpeelE.J.M. Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines Int. J. Cancer 136 E207 218 2015 10.1002/ijc.29112537055525082736 Search in Google Scholar

48 Gao G., Wang J., Kasperbauer J.L., Tombers N.M., Teng F., Gou H., Zhao Y., Bao Z., Smith D.I.: Whole genome sequencing reveals complexity in both HPV sequences present and HPV integrations in HPV-positive oropharyngeal squamous cell carcinomas. BMC Cancer, 19, 1–15 (2019) GaoG. WangJ. KasperbauerJ.L. TombersN.M. TengF. GouH. ZhaoY. BaoZ. SmithD.I. Whole genome sequencing reveals complexity in both HPV sequences present and HPV integrations in HPV-positive oropharyngeal squamous cell carcinomas BMC Cancer 19 1 15 2019 10.1186/s12885-019-5536-1646054030975103 Search in Google Scholar

49 Koneva L.A., Zhang Y., Virani S., Hall P.B., McHugh J.B., Chepeha D.B., Wolf G.T., Carey T.E., Rozek L.S., Sartor M.A.: HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. Mol. Cancer Res. 16, 90–102 (2018) KonevaL.A. ZhangY. ViraniS. HallP.B. McHughJ.B. ChepehaD.B. WolfG.T. CareyT.E. RozekL.S. SartorM.A. HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers Mol. Cancer Res. 16 90 102 2018 10.1158/1541-7786.MCR-17-0153575256828928286 Search in Google Scholar

50 Mellin H., Dahlgren L., Munck-Wikland E., Lindholm J., Rabbani H., Kalantari M., Dalianis T.: Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int. J. Cancer, 102, 152–158 (2002) MellinH. DahlgrenL. Munck-WiklandE. LindholmJ. RabbaniH. KalantariM. DalianisT. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer Int. J. Cancer 102 152 158 2002 10.1002/ijc.1066912385011 Search in Google Scholar

51 Nulton T.J., Kim N.K., DiNardo L.J., Morgan I.M., Windle B.: Patients with integrated HPV16 in head and neck cancer show poor survival. Oral Oncol. 80, 52–55 (2018) NultonT.J. KimN.K. DiNardoL.J. MorganI.M. WindleB. Patients with integrated HPV16 in head and neck cancer show poor survival Oral Oncol. 80 52 55 2018 10.1016/j.oraloncology.2018.03.015593038429706188 Search in Google Scholar

52 Mandel P., Metais P.: Les acides nucleiques du plasma sanguin chez l’Homme. C R Seances Soc. Biol. Fil. 142, 241–243 (1948) MandelP. MetaisP. Les acides nucleiques du plasma sanguin chez l’Homme C R Seances Soc. Biol. Fil. 142 241 243 1948 Search in Google Scholar

53 Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J.: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646–650 (1977) LeonS.A. ShapiroB. SklaroffD.M. YarosM.J. Free DNA in the serum of cancer patients and the effect of therapy Cancer Res. 37 646 650 1977 Search in Google Scholar

54 Diaz Jr L.A., Bardelli A.: Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579–586 (2014) Diaz JrL.A. BardelliA. Liquid biopsies: genotyping circulating tumor DNA J. Clin. Oncol. 32 579 586 2014 10.1200/JCO.2012.45.2011482076024449238 Search in Google Scholar

55 Lo Y.M., Zhang J., Leung T.N., Lau T.K., Chang A.M., Hjelm N.M.: Rapid clearance of fetal DNA from maternal plasma. Am. J. Hum. Genet. 64, 218–224 (1999) LoY.M. ZhangJ. LeungT.N. LauT.K. ChangA.M. HjelmN.M. Rapid clearance of fetal DNA from maternal plasma Am. J. Hum. Genet. 64 218 224 1999 10.1086/30220513777209915961 Search in Google Scholar

56 Yu S.C., Lee S.W., Jiang P., Leung T.Y., Chan K.A., Chiu R.W., Lo Y.D.: High-resolution profiling of fetal DNA clearance from maternal plasma by massively paralel sequencing. Clin. Chem. 59, 1228–1237 (2013) YuS.C. LeeS.W. JiangP. LeungT.Y. ChanK.A. ChiuR.W. LoY.D. High-resolution profiling of fetal DNA clearance from maternal plasma by massively paralel sequencing Clin. Chem. 59 1228 1237 2013 10.1373/clinchem.2013.20367923603797 Search in Google Scholar

57 Emlen W., Mannik M.: Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA. Clin. Exp. Immunol. 56, 185–192 (1984) EmlenW. MannikM. Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA Clin. Exp. Immunol. 56 185 192 1984 Search in Google Scholar

58 Diehl F., Vogelstein B. i wsp.: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA, 102, 16368–16373 (2005) DiehlF. VogelsteinB. Detection and quantification of mutations in the plasma of patients with colorectal tumors Proc. Natl. Acad. Sci. USA 102 16368 16373 2005 10.1073/pnas.0507904102128345016258065 Search in Google Scholar

59 Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., Knippers R.: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659–1665 (2001) JahrS. HentzeH. EnglischS. HardtD. FackelmayerF.O. HeschR.D. KnippersR. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells Cancer Res. 61 1659 1665 2001 Search in Google Scholar

60 Mouliere F., Thierry A.R. i wsp.: Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Transl. Oncol. 6, 319–328 (2013) MouliereF. ThierryA.R. Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load Transl. Oncol. 6 319 328 2013 10.1593/tlo.12445366080123730412 Search in Google Scholar

61 Sacher AG, Paweletz C, Dahlberg SE, Alden R.S., O’Connell A., Feeney N., Mach S.L., Jänne P.A., Oxnard G.R.: Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2, 1014–1022 (2016) SacherAG PaweletzC DahlbergSE AldenR.S. O’ConnellA. FeeneyN. MachS.L. JänneP.A. OxnardG.R. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer JAMA Oncol. 2 1014 1022 2016 10.1001/jamaoncol.2016.0173498279527055085 Search in Google Scholar

62 Kuo Y.B., Chen J.S., Fan C.W. Li Y.S., Chan E.C.: Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin. Chim. Acta, 433, 284–289 (2014) KuoY.B. ChenJ.S. FanC.W. LiY.S. ChanE.C. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer Clin. Chim. Acta 433 284 289 2014 10.1016/j.cca.2014.03.02424685572 Search in Google Scholar

63 Han J.Y., Choi J.J., Kim J.Y., Han Y.L., Lee G.K.: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. BMC Cancer, 16, 1–10 (2016) HanJ.Y. ChoiJ.J. KimJ.Y. HanY.L. LeeG.K. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer BMC Cancer 16 1 10 2016 10.1186/s12885-016-2678-2 Search in Google Scholar

64 Pathak A.K., Bhutani M., Kumar S., Mohan A., Guleria R.: Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin. Chem. 52, 1833–1842 (2006) PathakA.K. BhutaniM. KumarS. MohanA. GuleriaR. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool Clin. Chem. 52 1833 1842 2006 Search in Google Scholar

65 Schwarzenbach H., Hoon D.S., Pantel K.: Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer, 11, 426–437 (2011) SchwarzenbachH. HoonD.S. PantelK. Cell-free nucleic acids as biomarkers in cancer patients Nat. Rev. Cancer 11 426 437 2011 10.1038/nrc306621562580 Search in Google Scholar

66 van Ginkel J.H., Slieker F.J.B., de Bree R., van Es R.J., Van Cann E.M., Willems S.M.: Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature. Oral Oncol. 75, 8–15 (2017) van GinkelJ.H. SliekerF.J.B. de BreeR. van EsR.J. Van CannE.M. WillemsS.M. Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature Oral Oncol. 75 8 15 2017 10.1016/j.oraloncology.2017.10.00729224828 Search in Google Scholar

67 Swiecicki P.L., Brennan J.R., Mierzwa M., Spector M.E., Brenner J.C.: Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers. Laryngoscope, 129, 1836–1843 (2019) SwiecickiP.L. BrennanJ.R. MierzwaM. SpectorM.E. BrennerJ.C. Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers Laryngoscope 129 1836 1843 2019 10.1002/lary.27725658654630570748 Search in Google Scholar

68 Keller L., Belloum Y., Wikman H., Pantel K.: Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br. J. Cancer, 124, 345–358 (2021) KellerL. BelloumY. WikmanH. PantelK. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond Br. J. Cancer 124 345 358 2021 10.1038/s41416-020-01047-5785255632968207 Search in Google Scholar

69 Jakobsen K.K., Carlander A.F., Bendtsen S.K., Garset-Zamani M., Lynggaard C.D., Grønhøj C., von Buchwald C.: Diagnostic Accuracy of HPV Detection in Patients with Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis. Viruses, 13, 1692 (2021) JakobsenK.K. CarlanderA.F. BendtsenS.K. Garset-ZamaniM. LynggaardC.D. GrønhøjC. von BuchwaldC. Diagnostic Accuracy of HPV Detection in Patients with Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis Viruses 13 1692 2021 10.3390/v13091692847300134578274 Search in Google Scholar

70 Wuerdemann N., Jain R., Adams A., Speel E.J.M., Wagner S., Joosse S. A., Klussmann J.P.: Cell-Free HPV-DNA as a Biomarker for Oropharyngeal Squamous Cell Carcinoma-A Step Towards Personalized Medicine? Cancers, 12, 2997 (2020) WuerdemannN. JainR. AdamsA. SpeelE.J.M. WagnerS. JoosseS.A. KlussmannJ.P. Cell-Free HPV-DNA as a Biomarker for Oropharyngeal Squamous Cell Carcinoma-A Step Towards Personalized Medicine? Cancers 12 2997 2020 10.3390/cancers12102997760270233076524 Search in Google Scholar

71 Lee J.Y., Bhide S.: Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. Brit. J. Cancer, 117, 876–883 (2017) LeeJ.Y. BhideS. Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma Brit. J. Cancer 117 876 883 2017 10.1038/bjc.2017.258558999928809864 Search in Google Scholar

72 Dermody S.M., Haring C.T., Bhambhani C., Tewari M., Brenner J.C., Swiecicki P.L.: Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA. Curr. Treat. Option On. 22, 1–11 (2021) DermodyS.M. HaringC.T. BhambhaniC. TewariM. BrennerJ.C. SwiecickiP.L. Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA Curr. Treat. Option On. 22 1 11 2021 10.1007/s11864-021-00821-8841130133559043 Search in Google Scholar

73 Mazurek A.M., Fiszer-Kierzkowska A., Rutkowski T., Składowski K., Pierzyna M., Ścieglińska D., Woźniak G., Głowacki G., Kawczyński R., Małusecka E.: Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma. Cancer Biomark. 13, 385–394 (2013) MazurekA.M. Fiszer-KierzkowskaA. RutkowskiT. SkładowskiK. PierzynaM. ŚcieglińskaD. WoźniakG. GłowackiG. KawczyńskiR. MałuseckaE. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma Cancer Biomark. 13 385 394 2013 10.3233/CBM-13037124440979 Search in Google Scholar

74 Pérez-Barrios C., Nieto-Alcolado I., Torrente M., Jiménez-Sánchez C., Calvo V., Gutierrez-Sanz L., Palka M., Donoso-Navarro E., Provencio M., Romero A.: Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl. Lung Cancer Res. 5, 665–672 (2016) Pérez-BarriosC. Nieto-AlcoladoI. TorrenteM. Jiménez-SánchezC. CalvoV. Gutierrez-SanzL. PalkaM. Donoso-NavarroE. ProvencioM. RomeroA. Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing Transl. Lung Cancer Res. 5 665 672 2016 10.21037/tlcr.2016.12.03523387828149760 Search in Google Scholar

75 Capone R.B., Pai S.I., Koch W.M., Gillison M.L., Danish H.N., Westra W.H., Daniel R., Shah K.V., Sidransky D.: Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res. 6, 4171–4175 (2000) CaponeR.B. PaiS.I. KochW.M. GillisonM.L. DanishH.N. WestraW.H. DanielR. ShahK.V. SidranskyD. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma Clin. Cancer Res. 6 4171 4175 2000 Search in Google Scholar

76 Cao H, Le Q.T. i wsp.: Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. Int. J. Radiat. Oncol. Bio.l Phys. 82, e351–e358 (2012) CaoH LeQ.T. Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients Int. J. Radiat. Oncol. Bio.l Phys. 82 e351 e358 2012 10.1016/j.ijrobp.2011.05.061325741121985946 Search in Google Scholar

77 Mazurek A.M., Rutkowski T., Śnietura M., Pigłowski W., Suwiński R., Składowski K.: Detection of circulating HPV16 DNA as a biomarker in the blood of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head Neck, 41, 632–641 (2019) MazurekA.M. RutkowskiT. ŚnieturaM. PigłowskiW. SuwińskiR. SkładowskiK. Detection of circulating HPV16 DNA as a biomarker in the blood of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma Head Neck 41 632 641 2019 10.1002/hed.2536830566259 Search in Google Scholar

78 Ahn S.M., Chan J.Y., Zhang Z., Wang H., Khan Z., Bishop J.A., Westra W., Koch W.M., Califano J.A.: Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol. Head Neck Surg. 140, 846–854 (2014) AhnS.M. ChanJ.Y. ZhangZ. WangH. KhanZ. BishopJ.A. WestraW. KochW.M. CalifanoJ.A. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer JAMA Otolaryngol. Head Neck Surg. 140 846 854 2014 10.1001/jamaoto.2014.1338431390425078109 Search in Google Scholar

79 Hindson C.M., Chevillet J.R., Briggs H.A., Gallichotte E.N., Ruf I.K., Hindson B.J., Vessella R.L., Tewari M.: Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods, 10, 1003–1005 (2013) HindsonC.M. ChevilletJ.R. BriggsH.A. GallichotteE.N. RufI.K. HindsonB.J. VessellaR.L. TewariM. Absolute quantification by droplet digital PCR versus analog real-time PCR Nat. Methods 10 1003 1005 2013 10.1038/nmeth.2633411867723995387 Search in Google Scholar

80 Chera B.S., Gupta G.P. i wps.: Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clin. Cancer Res. 25, 4682–4690 (2019) CheraB.S. GuptaG.P. Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer Clin. Cancer Res. 25 4682 4690 2019 10.1158/1078-0432.CCR-19-0211667976631088830 Search in Google Scholar

81 Hanna G.J., Supplee J.G., Kuang Y., Mahmood U., Lau C.J., Haddad R.I., Jänne P.A., Paweletz C.P. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. Ann. Oncol. 29, 1980–1986 (2018) HannaG.J. SuppleeJ.G. KuangY. MahmoodU. LauC.J. HaddadR.I. JänneP.A. PaweletzC.P. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer Ann. Oncol. 29 1980 1986 2018 10.1093/annonc/mdy25130010779 Search in Google Scholar

82 Dahlstrom K.R., Li G., Hussey C.S., Mahmood U., Lau C.J., Haddad R.I., Jänne P.A., Paweletz C.P.: Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. Cancer, 121, 3455–3464 (2015) DahlstromK.R. LiG. HusseyC.S. MahmoodU. LauC.J. HaddadR.I. JänneP.A. PaweletzC.P. Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer Cancer 121 3455 3464 2015 10.1002/cncr.29538457561226094818 Search in Google Scholar

83 Dok R., Nuyts S.: HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers, 8, 41 (2016) DokR. NuytsS. HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies Cancers 8 41 2016 10.3390/cancers8040041 Search in Google Scholar

84 Kawecki A., Nawrocki S., Golusiński W., Grzesiakowska U., Jassem J., Krajewski R., Olszewski W.: Nowotwory nabłonkowe narządów głowy i szyi. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Sierpień 2014r. http://onkologia.zalecenia.med.pl/pdf/zalecenia_PTOK_tom1_01_Nowotwory_nablonkowe_glowy_i_szyi_20140807.pdf (16.06.2020) KaweckiA. NawrockiS. GolusińskiW. GrzesiakowskaU. JassemJ. KrajewskiR. OlszewskiW. Nowotwory nabłonkowe narządów głowy i szyi. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych Sierpień 2014r. http://onkologia.zalecenia.med.pl/pdf/zalecenia_PTOK_tom1_01_Nowotwory_nablonkowe_glowy_i_szyi_20140807.pdf (16.06.2020) Search in Google Scholar

85 Hanna G.J., Lau C.J., Mahmood U., Supplee J.G., Mogili A.R., Haddad R. Jännea P.A., Paweletz C.P.: Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol. 95, 120–126 (2019) HannaG.J. LauC.J. MahmoodU. SuppleeJ.G. MogiliA.R. HaddadR. JänneaP.A. PaweletzC.P. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer Oral Oncol. 95 120 126 2019 10.1016/j.oraloncology.2019.06.019 Search in Google Scholar

86 Lell M., Baum U., Greess H., Nömayr A., Nkenke E., Koester M., Lenz M., Bautz W.: Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur. J. Radiol. 33, 239–247 (2000) LellM. BaumU. GreessH. NömayrA. NkenkeE. KoesterM. LenzM. BautzW. Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI Eur. J. Radiol. 33 239 247 2000 10.1016/S0720-048X(99)00120-5 Search in Google Scholar

87 Rutkowski T.W., Widłak P.: Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer. J. Transl. Med. 18, 1–10 (2020) RutkowskiT.W. WidłakP. Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer J. Transl. Med. 18 1 10 2020 10.1186/s12967-020-02330-y715803332293457 Search in Google Scholar